chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No initial reactions on 1st or 2nd shot.  One month later, awoke with severe vertigo; nauseia, total lathargic feeling  This lasted all day. 2nd day, awoke with same but by afternoon felt fine. Days 3-4 same feeling each  morning, but by afternoon no dizziness or weakness. Day 5 woke up feeling normal like the prior 4 days  had not happened.  Two weeks later, awoke with dizziness and again weak feeling. If tilted head back to look up it would bring me to my knees with dizzy feeling. Lasted all day, then the next day same dizziness when waking but by afternoon felt just fine. That time it only lasted 2 days.
Provider discharge summary "Patient is a 64 yr old female with a past medical history significant for CHF, Type 2 DM, ILD on 2L chronically who presents to the ED with right foot pain and shortness of breath. Patient does have chronic shortness of breath, known with ILD on 2L at home which she does increase to 4-6L when she is in the shower due to exertion. She was found to be COVID positive in the ER. In the ED, the patient was noted to have SpO2 of 95% on 3L NC, shortly later increased to 5L NC with improvement of tachypnea and dyspnea. CXR unrevealing, 3V x-ray of right foot showing significant arthritis with osteophytes and "excrescence at the dorsal head of the talus and subtalar coalition." CBC revealed macrocytic anemia (unchanged from previous), ESR >130, magnesium 1.6. BNP showing 2516 (previous elevation 2444), CRP 7.5, procalcitonin 0.10, D-dimer 650 (previous elevations 1100), though CTPA negative for pulmonary embolism. Patient was admitted for acute on chronic respiratory failure secondary to COVID-19. Patient initially placed on her home oxygen levels while during this inpatient stay, though required increased oxygen support with transition to high flow nasal cannula. Her foot pain likely attributed to an acute gout flare up as her serum uric acid was elevated and symptoms resolved with use of prednisone. She has completed course of remdesivir. She was not given steroids on discharge. Her home Lopressor  was decreased from 50mg to 12.5mg BID during this admission, due to bradycardia. She is to continue her other home medications as prescribed. She is to follow with her PCP. Recommend further workup of incidental adrenal mass per PCP. Patient's oxygen requirements improved and she was transitioned to her home oxygen of 3L. She is medically stable and ready for discharge in the afternoon of January 28, 2022."
Redness at injection site, Arm is still pink; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at injection site, Arm is still pink) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (Redness at injection site, Arm is still pink). At the time of the report, VACCINATION SITE ERYTHEMA (Redness at injection site, Arm is still pink) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported No treatment drugs were reported
lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023; No adverse event; lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023, it was administered to patient on 04-Mar-2023; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023), POOR QUALITY PRODUCT ADMINISTERED (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023, it was administered to patient on 04-Mar-2023) and NO ADVERSE EVENT (No adverse event) in a 2-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1903B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Mar-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2023, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023, it was administered to patient on 04-Mar-2023). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023), POOR QUALITY PRODUCT ADMINISTERED (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023, it was administered to patient on 04-Mar-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023) and POOR QUALITY PRODUCT ADMINISTERED (lot numbers AS1903B was involved in a temperature excursion that took place at HCP office on 13-Feb-2023, it was administered to patient on 04-Mar-2023).    No concomitant drug was reported. It was unknown whether patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No treatment drug was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-715951 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-715951:Master Case - Child
Triggered an episode of Bell's palsy; Patient had one other incident of this and sought medical advice a few years ago.; This is a spontaneous report from a non-contactable consumer or other nonhealthy care professional (the patient). A 23-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation, Solution for injection, Batch/Lot Number: EW0178) via an unspecified route of administration on 23Jul2021 (at the age of 23-years-old) as dose 2, single for covid-19 immunisation at  Clinic/facility. The patient medical history included Bells palsy from an unknown date and Unknown if ongoing. Concomitant medications were not reported. No other medications the patient received within 2 weeks of vaccination. Prior to vaccination patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. Historical vaccine included as the patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation, Solution for injection, Batch/Lot Number: EW0186) via unspecified route of administration, administered on 28Jun2021 at the age of (23-years-old) as a single dose for covid-19 immunisation. It was reported that patient received the second dose of the vaccine (Pfizer-BioNtech) on Friday(23Jul2021) triggered an episode of Bell's palsy today Sunday (25Jul2021). Patient had one other incident of this and sought medical advice a few years ago. This incident was more mild than the original case but still it was very noticeable. No treatment received for the reported AE. Outcome of the events was not recovered.   Follow-Up: Follow-up attempts are completed. No further information is expected.
This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (11 Doses administered after 30-day Use By Date) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031H21A) for COVID-19 vaccination. No Medical History information was reported. On 05-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (11 Doses administered after 30-day Use By Date). On 05-Jan-2022, EXPIRED PRODUCT ADMINISTERED (11 Doses administered after 30-day Use By Date) had resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. Concomitant medication was not reported. Treatment information was not reported.
Swelling; redness; itching around both eyes; Face and nose mildly swollen; Face and nose mildly swollen; Intermittent coughing; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 16 year-old female patient (not pregnant) received bnt162b2 (COMIRNATY), administered in arm left, administration date 13Nov2021 10:30 (Batch/Lot number: unknown) at the age of 16 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Allergy to nuts" (unspecified if ongoing), notes: Peanuts. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Unable to locate or read the details), for COVID-19 immunization. The following information was reported: SWELLING (non-serious) with onset 13Nov2021 13:00, outcome "recovering", described as "Swelling"; ERYTHEMA (non-serious) with onset 13Nov2021 13:00, outcome "recovering", described as "redness"; EYE PRURITUS (non-serious) with onset 13Nov2021 13:00, outcome "recovering", described as "itching around both eyes"; SWELLING FACE (non-serious), NASAL OEDEMA (non-serious) all with onset 13Nov2021 13:00, outcome "recovering" and all described as "Face and nose mildly swollen"; COUGH (non-serious) with onset 13Nov2021 13:00, outcome "recovering", described as "Intermittent coughing". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of swelling, erythema, eye pruritus, swelling face, nasal oedema, cough.  Additional Information: Patient receive any other vaccines within 4 weeks prior to the COVID vaccine was no. Treatment received for the adverse event was medication and steroids.  Prior to vaccination, was the patient diagnosed with COVID-19 was yes. Since the vaccination, patient has not been tested for COVID-19 was no. The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.  Follow-up (16Dec2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Upper Torso Rash; Rash is still going on the injection site; Some Injection site pain; Injection site was red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Some Injection site pain), RASH (Upper Torso Rash), INJECTION SITE ERYTHEMA (Injection site was red) and VACCINATION SITE RASH (Rash is still going on the injection site) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PAIN (Some Injection site pain) and INJECTION SITE ERYTHEMA (Injection site was red). On 16-Jan-2021, the patient experienced RASH (Upper Torso Rash) and VACCINATION SITE RASH (Rash is still going on the injection site). On 16-Jan-2021, VACCINATION SITE PAIN (Some Injection site pain) had resolved. At the time of the report, RASH (Upper Torso Rash), INJECTION SITE ERYTHEMA (Injection site was red) and VACCINATION SITE RASH (Rash is still going on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment and concomitant medications were not provided by reporter.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Swelling between armpit and chest; Body aches; Headache; Fatigue; Booster\ received dose 3; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 11Oct2021 at 14:00 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma and known allergies to dust, dogs and cats. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included collagen (MANUFACTURER UNKNOWN), melatonin (MANUFACTURER UNKNOWN) all for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 21Jan2021 at 18:00 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. The patient previously received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 19Feb2021 at 16:00 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. On 12Oct2021 at 12:00 AM, the patient experienced swelling between armpit and chest, body aches, headache and fatigue. No therapeutic measures were taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swelling between armpit and chest, body aches, headache and fatigue was resolving at the time of the report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Rash on wrist, shoulders, neck face and back.  Was seen at Urgent Care and personal physician's office. Was treated with prednisone.
This case was reported by a consumer (also the subject's mother) and described the occurrence of injection swelling in a 15-month-old male subject who was vaccinated with Dtap vaccine (GlaxoSmithKline). A physician or other health care professional has not verified this report. Concurrent medical conditions included ear infection. Concurrent vaccinations included 5 unspecified vaccines; manufacturer unspecified given on the same unspecified date as the Dtap vaccine. Concurrent medications included Multivitamin + fluoride. On an unspecified date the subject received a dose of Dtap vaccine (details unknown) as the 2nd or 3rd dose in the series. Less than one day after vaccination with Dtap vaccine, the subject experienced injection site swelling. The mother reported that the subject experienced "baseball size swelling at the site of the injection". She noted that the subjected received 5 vaccinations that day: 2 in one arm and 3 in the other. As she best recalls, she believed the swelling was with the Dtap site. At the time of reporting the event was resolved.
I have had body pain for about 1 week and recently started developing a rash/bumbs that is spreading daily on my upper back stomach and back of my hands. Also skin on the stomach has red patches
extreme tiredness leading to joint pain about 5 hours after injection...patient went to bed and woke up in the middle of the night with a terrible headache
Headache for 3 days (3/12-3/14) & muscle aches & lower back pain 3/14-3/20 & major fatigue 3/13-3/20.  I took Extra strength Tylenol for the headache. I took Tylenol during the day for muscle aches & lower back;  & Tizanidine muscle relaxer each night. By 3/18 I was exhausted & slept from 6:30 pm 3/18 to 9:45pm on 3/19. Was awake 1.5 hrs & was back to bed sleeping until 8:45am on 3/20/21.
Patient reports warmth and redness at the injection site. Patient also reports cold sweats, body aches, and nausea after vaccination. Patient reported to PCP on 10/21 and was told to take ZYRTEC and ice the area. Patient was prescribed cephalexin but told only to take if reaction becomes worse.
No adverse side effect till 7days post vaccine. One seventh day woke up with severe dizziness, headache, brain fog, fatigue and periodic brain zaps. This has been ongoing since March 5, (15 days).
Starting with throat closing, difficulty swallowing. By the time we reached the ER I became very lightheaded.
Hospitalization for COVID on dates  05/02/2022- 05/08/2022. ?Treated with Duoneb as needed, Vitamin C 500mg PO daily, baricitinib 4mg PO daily, ceftriaxone 1g IV daily, Vitamin D3 25mcg  PO daily, dexamethasone 6mg IV daily, azithromycin 500mg IV daily, zinc 50mg PO daily.
Redness, swelling, itching, warmth treated with WESTCORT cream, ice, BENADRYL.
Forty eight hours after vaccination, left upper arm tender. No redness or swelling, otherwise well. Treated by covering doctor with oral antibiotics, resolution in 48 hours.
pt recv vax 13NOV cam in urgent care 19NOV c/o rx facial weakness;h/a started day a/eye wouldn't blink rt;pt given pred;
Large, bright red mark over injection site that continued to get worse for several days (Tuesday - Friday). It was Painful to the touch through Thursday, then became itchy.  It began to fade in color on Saturday and Sunday, and is now pale, though there is a still a small lump where it occurred.
1 inch X 1 1/4 inch upper arm redness, blanches, not warm, no streaking c/w immunization reaction
Area started itching really bad; readness started around the injection site/arm was red but it was about the size of a 50cent piece; Arm started feeling sore which i expected cause it happened with my second dose as well; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Area started itching really bad), VACCINATION SITE ERYTHEMA (readness started around the injection site/arm was red but it was about the size of a 50cent piece) and MYALGIA (Arm started feeling sore which i expected cause it happened with my second dose as well) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 024M20A and 026L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypersensitivity, Guttate psoriasis since November 2014, Diabetic since July 2020, Spice allergy (Paprika, Throat starts to seal), Drug allergy (Ibuprofen, nausea to the point of dehydration can't keep solids or liquids down) and Drug allergy (Meloxicam, nausea to the point of dehydration can't keep solids or liquids down).   On 25-Jan-2021 at 2:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021 at 2:15 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (Area started itching really bad), VACCINATION SITE ERYTHEMA (readness started around the injection site/arm was red but it was about the size of a 50cent piece) and MYALGIA (Arm started feeling sore which i expected cause it happened with my second dose as well). At the time of the report, PRURITUS (Area started itching really bad), VACCINATION SITE ERYTHEMA (readness started around the injection site/arm was red but it was about the size of a 50cent piece) and MYALGIA (Arm started feeling sore which i expected cause it happened with my second dose as well) outcome was unknown.            No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2021-340995 (Patient Link).
Patient came in to our hospital outpatient pharmacy to receive the second dose of Pfizer COVID-19 vaccine.  Patient reported history of asthma and an anaphylactic aspirin allergy during initial pre-vaccine questionnaire.  Dose given 3:36PM and patient told to wait inside pharmacy due to history of allergic reactions.  Patient began having itching and rashes behind ear.  Was given water and 50mg diphenhydramine orally when rash appeared.  Patient's breathing became labored and patients husband gave her the patients albuterol inhaler.  She took two puffs and was laid down on the floor on a mat when breathing did not improve.  ED/EMS was contacted.  Patient began having ineffective breaths and 1 dose of generic EpiPen (NDC 49502-0102-02 exp 05/22) was given.  Breathing quickly improved.  ED physicians arrived minutes following EpiPen dose and patient was taken to ED for further evaluation and treatment.
palpitations and elevated troponins. History of palpitations in past. Presented with thumping discomfort in front of chest. SOB.  Pt lost to follow up.  Symptoms: PALPITATIONS(R002).
Tingling on left side spread to different parts of left side of my body and I was sent to emergency room where I was admitted overnight.
Pt. states that after receiving the 3rd dose of Moderna 11/03/2021, started experiencing symptoms 11/24/2021 of Tested Positive HIV factors while registering to donate Blood /later documents mailed with Negative results 11/30/2021. Also received the Influenza Vaccine 11/12/2021.
Patient sent by EMS 5/16 for being more lethargic at home for the last 2 days. She is a hospice patient with Hospice. Family states she had a recent covid exposure, has been more weak, and they have been unable to turn/change her. Patient currently states she feels good and is no pain. Denies CP, SOB, fevers, chills, n/v. Patient due to mental status issues, is unable to provide me any history. All history is from the chart. Patient's admission chest x-ray showed no acute process with COVID testing 5/16 showing positive results with negative flu A and B. Maintained on Rocephin. On day of DC, pt is stable for discharge home 5/23.  Patient is feeling better, denies CP, SOB, HA, dizziness.
Developed left shoulder pain after initial COVID vaccine. This increased gradually and by 6/22/2021, she was unable to reach and grab (mobility decreased). Physical therapy prescribed.
symptoms: severe generalized body pain, red swollen and painful injection site, fever, nausea, headache, and generalized weakness. I did not go to the hospital. I was able to manage myself.
Inappropriate schedule of drug administration; no adverse effect Information has been received from a registered nurse (RN) concerning a 4 month old patient with no pertinent medical history or allergies in approximately May 2006, was vaccinated PO with the first 2.0ml dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human-bovine). There was no concomitant therapy. Unspecified medical attention was sought and no laboratory/diagnostic tests were performed. No adverse reaction was reported. Additional information has been requested.
Patient was given flu shot in left arm. Patient was then given Gardasil 9 in right arm. Immediately after Gardasil admin pt. passed out. She was placed in floor + EMS arrived. Pt. was okay + checked out OK By EMS
Information has been received from a registered nurse concerning a 15 year old female who was vaccinated with a dose of Gardasil (Lot # 654741/1208F).  Concomitant therapy included FLOXIN, amoxicillin and albuterol.  Subsequently the patient developed diabetes.  Unspecified medical attention was sought.  At the time of the report the patient's outcome was unknown.  Additional information has been requested.